Quarterly Result22 May 2025, 01:39 pm
Strides Pharma Science Ltd Delivers Strong FY25 Results, Exceeding Outlook Across All Metrics
AI Summary
Strides Pharma Science Ltd has announced its consolidated financial results for the quarter and full year ended March 31, 2025. The company's revenue grew by 17.2% YoY, exceeding the outlook communicated. The US business recorded $291m in revenue, representing 21.8% YoY growth. The company also delivered an operating PAT of $3,447m for FY25, reflecting continued focus on profitability. The Board has recommended a dividend of 4 per share for FY25.
Key Highlights
- FY25 revenue grew by 17.2% YoY, outperforming the guidance of 12-15%
- EBITDA outlook surpassed, delivering $8,028m in FY25
- Net debt reduced by $5,128m, improving Net Debt-to-EBITDA ratio to 1.9x
- US business recorded $291m in revenue, representing 21.8% YoY growth
- Operating PAT of $3,447m for FY25, reflecting continued focus on profitability